Fig. 3From: The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDSDistribution of the total sample of the patients according to their responses in the 8-point NIAID-OS scale at baseline and at Day 7. NIAID-OS National Institute of Allergy and Infectious Diseases ordinal scale, NIV non-invasive ventilationBack to article page